Pain & Inflammation

Clinical Context

Chronic pain remains one of the largest and most expensive healthcare burdens globally.

According to the CDC, chronic pain affects millions of adults in the United States and is associated with reduced mobility, decreased quality of life, impaired daily functioning, and increased healthcare utilization. Chronic pain severe enough to interfere with daily activities affects a substantial portion of the population.

At the same time, healthcare systems are increasingly adopting:

• opioid sparing recovery pathways
• multimodal pain management
• non-pharmacologic interventions
• decentralized recovery workflows
• outpatient rehabilitation models

Initial Commercial Focus

Electrome's commercial deployment strategy is initially focused on:

• musculoskeletal pain
• inflammation-related recovery
• postoperative support
• plantar fasciitis
• osteoarthritis related pain
• wearable recovery workflows

The Shift Toward Non-Drug Recovery

Over the past decade, growing concern surrounding opioid exposure and chronic pain management has accelerated interest in non-pharmacologic therapeutic options.

Organizations including the CDC, CMS, the Veterans Health Administration, and the ERAS Society have increasingly emphasized multimodal and opioid sparing approaches to pain and recovery management.

Wearable bioelectric therapy systems may offer several characteristics relevant to this transition:

• non-invasive delivery
• low systemic burden
• wearable use models
• integration into outpatient recovery
• potential support for decentralized care workflows

"Healthcare systems are actively looking for scalable opioid sparing recovery solutions. Bioelectric therapeutics may become an important component within broader multimodal recovery pathways."

What Is Pulsed Shortwave Therapy?

Pulsed Shortwave Therapy (PSWT) uses pulsed electromagnetic fields rather than conductive electrical stimulation. Unlike TENS systems, PSWT devices do not rely on electrical current passing through the skin via adhesive electrodes.

FDA-cleared wearable PSWT systems such as ActiPatch^® operate at a carrier frequency of 27.12 MHz and are designed for extended wearable use without requiring conductive gels or direct electrical stimulation.

Modern wearable PSWT systems are generally designed for low burden use, prolonged wearability, ambulatory recovery workflows, and home based recovery environments.

Electrome's commercial ecosystem builds upon this FDA-cleared foundation while expanding toward broader bioelectric infrastructure and AI-native therapeutic systems.

Scientific Rationale

Every tissue in the body operates through electrochemical signaling. Inflammation, healing, neural communication, cellular coordination, and tissue response all depend on membrane potentials, ion gradients, electrophysiology, and cellular signaling environments.

Bioelectric medicine explores whether precisely controlled energy delivery systems may help interact with or influence aspects of these signaling environments.

Electrome's broader platform strategy extends beyond individual devices toward signal response mapping, computational electrophysiology, Electrome Knowledge Graphs, AI assisted discovery systems, programmable therapeutic infrastructure, and bioelectric digital twins.

"Bioelectric signaling represents one of the most underexplored systems layers in medicine. We believe future computational systems may help researchers better understand how signaling environments influence recovery and tissue response."

Published Literature

Published literature involving pulsed shortwave and related electromagnetic modalities spans osteoarthritis, chronic musculoskeletal pain, postoperative recovery, plantar fasciitis, temporomandibular disorders, and fibromyalgia related investigations.

A randomized trial published in Clinical Rehabilitation evaluating pulsed shortwave therapy in osteoarthritis patients reported improvements in pain and function outcomes within the studied population.

Other studies have produced mixed or modest findings, emphasizing the importance of device specific evaluation, waveform architecture, treatment duration, patient selection, target indication, and endpoint design.

Electrome therefore emphasizes "supported by published clinical evidence" rather than broad efficacy claims. This evidence aware positioning is central to the company's scientific and regulatory philosophy.

Wearable Recovery Infrastructure

Electrome's commercial strategy extends beyond standalone devices toward integrated recovery infrastructure. The company's long term ecosystem vision includes:

• provider workflows
• wearable recovery support
• digital patient engagement
• outcomes tracking systems
• AI assisted therapeutic optimization

"Recovery is increasingly happening outside the hospital. We believe future recovery systems will combine wearable therapeutics, intelligent software, and decentralized patient engagement into a unified platform experience."

Current Commercial Status

Electrome's current commercial ecosystem includes FDA-cleared pulsed shortwave therapy infrastructure. However, not all future platform initiatives are commercialized, not all exploratory applications are clinically validated, and not all future therapeutic areas are FDA-cleared.

Electrome maintains a clear distinction between commercial products, pipeline programs, and exploratory research initiatives. This distinction is important for scientific, clinical, and regulatory clarity.